Cannakeys

Unlocking the Science of Cannabis

CK Home / Lysophosphatidylinositol (LPI) Cannabinoid Research

Lysophosphatidylinositol (LPI) Cannabinoid Research

Lysophosphatidylinositol (LPI) Research Dashboard

23

Primary Studies

5

Related Studies

28

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind human trials

2

Clinical human trials

Pre-Clinical Studies

8

Meta-analyses/Reviews

3

Animal studies

10

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 28 studies associated with Lysophosphatidylinositol (LPI).

Here is a small sampling of Lysophosphatidylinositol (LPI) studies by title:

  • The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling
  • Lysophosphatidylinositol: a novel link between ABC transporters and G-protein-coupled receptors
  • Expression of Lysophosphatidylinositol Signaling-relevant Molecules in Colorectal Cancer
  • Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning
  • Interactions between lysophosphatidylinositol receptor GPR55 and sphingosine-1-phosphate receptor S1P5 in live cells

Components of the Lysophosphatidylinositol (LPI) Research Dashboard

  • Top medical conditions associated with Lysophosphatidylinositol (LPI)
  • Proven effects in clinical trials for Lysophosphatidylinositol (LPI)
  • Receptors associated with Lysophosphatidylinositol (LPI)
  • Individual study details for Lysophosphatidylinositol (LPI)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Lysophosphatidylinositol (LPI)

Description of Lysophosphatidylinositol (LPI)

Lysophosphatidylinositol (LPI) is a bioactive lipid produced by the phospholipase A (PLA) family of lipases. LPI is posited to play a significant role in diverse physiological and pathological processes.


LPI is a proposed endogenous ligand/agonist for GPR55 (Roberto Piñeiro et al. 2012)


2-arachidonoyl lysophosphatidylinositol (2-ALPI)


2-LPI is a proposed endogenous ligand/agonist for GPR55 (Saori Oka et al. 2009)

Other Names:

Lysophosphatidylinositol

LPI: L-alpha-lysophosphatidylinositol; L-α-lysophosphatidylinositol


LPI IUPAC Name: [(2S)-2-hydroxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] acetate


LPI Molecular Formula: C11H21O12P


2-ALPI: 2-arachidonoyl-LPI; 2-arachidonoyl-lysophosphatidylinositol; 2-arachidonoyl-sn-glycero-3-phospho-D-myo-inositol 4,5-bisphosphate


2-ALPI IUPAC Name: [(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4-[[(2R)-3-hydroxy-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-oxidophosphoryl]oxy-6-phosphonatooxycyclohexyl] phosphate


2-ALPI Molecular Formula: C29H46O18P3-5


Source–PubChem

Lysophosphatidylinositol (LPI) Properties and Effects

The LPI/GPR55 axis: 


  • May worsen metabolic disorders (e.g., obesity, diabetes, inflammation)

  • May worsen developments and metastasis of certain cancer (e.g., breast cancer, colon cancer, uterine/endometrial cancer)

  • May worsen non-alcoholic steatosis & steatohepatitis

  • May worsen myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway

  • Inflammation (mixed results with some studies suggesting pro- vs anti-inflammatory effects)


 

Lysophosphatidylinositol (LPI) Receptor Binding

Endocannabinoid System (ECS) and LPI/2-LPI:


  • N/A


Endocannabinoidome (eBCome)and LPI/2-LPI:


  • GPR55 LPI is proposed agonist 

  • GPR55 2-LPI is proposed agonist

  • LPI activates TRPV2 (Kazuki Harada et al. 2017)


Inhibitors of LPI:


  • Δ9-tetrahydrocannabivarin, cannabidivarin, and cannabigerovarin (Sharon Anavi-Goffer et al. 2012); CBD (E Ryberg et al. 2007)

Top  

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.